Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia

Comprehensive Psychiatry

Volumn 43, Issue 6, 2002, Pages 469-473

  Liberman, Robert Paul ^a   Gutkind, Daniel ^a   Mintz, Jim ^a   Green, Michael ^a   Marshall, B D ^a   Robertson, Mary Jane ^a   Hayden, Jeffery ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LEARNING; MALE; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; REINFORCEMENT; SCHIZOPHRENIA; SELF CARE; TRAINING; TREATMENT OUTCOME; WORKING MEMORY;

EID: 0036853362     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1053/comp.2002.33499     Document Type: Article

References (23)

1. Falloon IRH, Liberman RP. Interactions between drug and psychosocial therapy in schizophrenia. Schizophr Bull 1983;9:543-554.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330.
3. Marder SR, Wirshing SC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996;153:1585-1592.
4. Corrigan PW, Wallace CJ, Schade ML, Green MF. Learning medication self-management skills in schizophrenia: Relationships with cognitive deficits and psychiatric symptoms Behav Ther 1994;25:5-15.
5. Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998;31:25-29.
6. Smith TE, Hull JW, Romanelli S, Fertuck E, Weiss KA. Symptoms and neurocognition as rate limiters in skills training for psychotic patients. Am J Psychiatry 1999;156:1817-1818.
7. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41(2 Suppl):S35-40.
8. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255.
9. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
10. Earnst KS, Taylor SF, Smet IC, Goldman RS, Tandon R, Berent S. The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia. Schizophr Res 1999;40:255-256.
11. Berman I, Klegon D, Fiedosewicz H, Chang H. The effect of novel antipsychotics on cognitive functioning. Psychiatr Ann 1999;29:643-646.
12. Addington J, Addington D. Neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol. Can J Psychiatry 1997;42:983-991.
13. Kane J, Honigfeld G, Singer J, Meltzer H, Group CCS. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
14. Glynn SM, Liberman RP, Bowen L, Kuehnel TG, Marshall BD, Gnanamuthu S. The Clinical Research Unit at Camarillo State Hospital. In: Corrigan PW, Liberman RP (eds). Behavior Therapy in Psychiatric Hospitals. New York, NY: Springer, 1994:39-60.
15. Harvey PD, Keefe RFE. Studies of the cognitive changes in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-184.
16. Paul GL, Tobias LT, Holly BL. Maintenance psychotropic drugs in the presence of active treatment programs: A triple blind withdrawal study with long-term mental patients. Arch Gen Psychiatry 1972;27:106-115.
17. Kern RS, Green MF, Wallace CJ. Declarative and procedural learning in schizophrenia: A test of the integrity of divergent memory systems. Cognit Neuropsychiatry 1997;2:39-50.
18. Meyers PS, Bond GR, Tunis SL, McCoy ML. Comparisons between atypical and traditional antipsychotics in work outcome for clients in a psychiatric rehabilitation program. Psychiatr Serv. In Press.
19. Aquila R. Vocational outcomes associated with conventional vs. atypical antipsychotic medications. Presented at the Annual Meeting of the American Psychiatric Association; May 16-20, 1999; Chicago, IL.
20. Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk S, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 1998;44:726-732.
21. Kee KS, Kern RS, Green MF. Perception of emotion and neurocognitive functioning in schizophrenia: What's the link? Psychiatry Res 1998;81:57-65.
22. Spaulding WD, Fleming SK, Reed D, Sullivan M, Storzbach D, Lam M. Cognitive functioning in schizophrenia: Implications for psychiatric rehabilitation. Schizophr Bull 1999;25:275-290.
23. Liberman RP, Marder SR, Marshall BD Jr, Mintz J, Kuehnel TG. Biobehavioral therapy: Interactions between pharmacotherapy and behavior therapy in schizophrenia. In: Wykes T, Tarrier N, Lewis S (eds). Outcome and Innovation in Psychological Treatment of Schizophrenia. London, UK: Wiley, 1998:179-199.